THYROLAR-3
LOE ApproachingNDAORALTABLET
Approved
Nov 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYROLAR-3 is an oral tablet indicated for thyroid hormone replacement therapy, approved in 1969 as an NDA product by AbbVie. The drug's mechanism of action and specific pharmacologic class are not currently documented in available data. It represents a legacy oral thyroid medication in the endocrinology space.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward cost management and generic transition support roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on THYROLAR-3 represents a career opportunity in late-lifecycle asset management and market transition strategy at a mature, legacy brand. Roles focus on maximizing remaining exclusivity value, managing generic transition, and supporting authorized generics rather than growth and innovation.
Brand ManagerCommercial Operations Analyst
Worked on THYROLAR-3 at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.